Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Detector-Agnostic Software

By Drug Discovery Trends Editor | November 26, 2012

Thermo Fisher Scientific Inc. offers the Thermo Scientific TraceFinder software version 2.1, designed for routine, high analytical throughput analysis of gas and liquid chromatography data.

The software now supports Thermo Scientific non-mass spectrometry detectors. This detector-agnostic package is designed for the quantitative and qualitative review of data for routine analyses.

TraceFinderTM software version 2.1 is designed to eliminate the need for multiple software packages when moving between most gas and liquid chromatographic techniques, and to simplify GC, GC-MS, HPLC, and LC-MS quantitation and targeted analysis. The software offers a workflow-driven method setup and automated data acquisition, data processing, and reporting capabilities. Methods developed with TraceFinder software can be shared between instruments and between laboratories. This sharing ability allows users to make methods readily available on new instruments. 

When using triple quadrupole GC-MS and LC-MS systems, the Compound Data Store (CDS) provides a list of selected reaction monitoring (SRM) experiments. Data review is customizable and assigns multiple flags to aid with quick identification of problem areas within a data set. To protect the integrity of analytical data, the software also includes a rights-based secure user login system.

Thermo Fisher Scientific Inc.


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE